Skip to main content
. Author manuscript; available in PMC: 2016 Jun 18.
Published in final edited form as: Chem Biol. 2015 Jun 4;22(6):755–763. doi: 10.1016/j.chembiol.2015.05.009

Figure 3. ARV-825 leads to more significant and longer lasting c-MYC suppression than small molecule inhibitors.

Figure 3

(A) Namalwa (left) and Ramos (right) cells were treated overnight with increasing doses of ARV-825 (up to 1.0 µM), or JQ1 (up to 10.0 µM), or OTX015 (up to 10.0 µM); lysates were analyzed by immunoblot for BRD4, c-MYC and actin.

(B) Namalwa cells were treated for 24 hours with ARV-825 (0.1 µM), JQ1 (1.0 µM) and OTX015 (1.0 µM M), followed by three washes to remove compounds, and re-seeded in fresh medium for various time points. Lysates were collected and analyzed by immunoblot for BRD4, c-MYC and actin.

(C) Namalwa cells were treated as in Figure 3B, RNA was extracted at 0, 6 and 24 hours post compounds removal, reverse-transcribed into cDNA and quantified by qPCR with SLC19A1 specific primers; GAPDH serves as internal control.